Compositions for delivery of liver stage antigens and related methods
AssigneeBioNTech SE
InventorsAsaf Poran, Daniel Abram Rothenberg, Theresa Addona, Raquel Mariska Furtado, Ugur Sahin, Thomas Ziegenhals
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding Plasmodium protein antigens.
Claims56
A polyribonucleotide encoding a polypeptide, wherein the polypeptide comprises one or more one or more Plasmodium T-cell antigens, wherein the one or more Plasmodium T cell antigens comprise two or more of:
- (i) an antigenic Plasmodium CSP polypeptide fragment;
- (ii) an antigenic Plasmodium LSA-1 (a) polypeptide fragment;
- (iii) an antigenic Plasmodium LSA-1 (b) polypeptide fragment;
- (iv) an antigenic Plasmodium TRAP polypeptide fragment;
- (v) an antigenic Plasmodium LSAP2 polypeptide fragment;
- (vi) an antigenic Plasmodium UIS3 polypeptide fragment;
- (vii) an antigenic Plasmodium ETRAMP10.3 polypeptide fragment;
- (viii) an antigenic Plasmodium LISP-1 polypeptide fragment;
- (ix) an antigenic Plasmodium LISP-2 polypeptide fragment;
- and
- (x) an antigenic Plasmodium LSA-3 polypeptide fragment.
A combination comprising:
- (i) a first pharmaceutical composition comprising a first polyribonucleotide, wherein the first polyribonucleotide encodes a first polypeptide, and the first polypeptide comprises one or more Plasmodium T-cell antigens;
- and
- (ii) a second pharmaceutical composition comprising a second polyribonucleotide, wherein the second polyribonucleotide encodes a second polypeptide, and the second polypeptide comprises one or more Plasmodium antigenic polypeptide regions or portions thereof.
A combination comprising:
- (i) a first pharmaceutical composition comprising a polyribonucleotide encoding a first polypeptide, wherein the first polypeptide comprises one or more Plasmodium T-cell antigens, and wherein the one or more Plasmodium T-cell antigens comprise a Plasmodium N-terminal region or portion thereof, but not a Plasmodium C-terminal region or portion thereof;
- and
- (ii) a second pharmaceutical composition comprising a polyribonucleotide encoding a second polypeptide, wherein the second polypeptide comprises one or more Plasmodium CSP polypeptide regions or portions thereof, and wherein the one or more Plasmodium CSP polypeptide regions or portions thereof comprise a Plasmodium CSP C-terminal region or portion thereof, but not a Plasmodium CSP N-terminal region or portion thereof.
Dependencies are inferred from the claim text.